Novartis wraps up acquisition of Takeda’s dry eye drug Xiidra

Swiss drugmaker Novartis has completed the acquisition of dry eye drug Xiidra (lifitegrast ophthalmic solution) 5% from Takeda for $3.4bn (£2.6bn) upfront in cash.